Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Thermo Fisher Sells Businesses Before Purchase of Life Technologies

By BiotechDaily International staff writers
Posted on 21 Jan 2014
On January 6, 2014, Thermo Fisher Scientific (Waltham, MA, USA) announced a USD 1.06 billion sale of multiple business units to GE Healthcare (Little Chalfont, United Kingdom), as a condition of regulatory approval for Thermo Fisher's acquisition of Life Technologies (Carlsbad, CA, USA).

The businesses sold to General Electric's life sciences arm include Thermo Fisher's cell culture, gene modulation, and magnetic beads units, which Thermo Fisher believes to have generated a combined USD 250 million in revenue over the past year. Goldman Sachs analysts said they do not expect the deal to have a major impact on Thermo Fisher's continued growth.

The divestiture has been expected since November 2013 when Thermo Fisher announced that it had reached an agreement with the European Commission to approve the purchase of Life Technologies.

If not for the sales announced on January 16, 2014, the acquisition would have left Thermo Fisher with almost 50% of the cell culture market. In the US, the Federal Trade Commission (FTC) approval for the Life Technologies purchase is still pending, but Thermo Fisher has stated that they do not expect the FTC to raise any additional hurdles.

In the genomics world, the USD 13.6 billion acquisition of Life Technologies has focused on Life's Ion Torrent arm, the gene sequencing unit that has been making gains against market leader Illumina. Ion Torrent has been noted for its rapid development and heavy investments in R&D, including a yet-unreleased semiconductor chip for the Ion Proton sequencer that could make the instrument competitive in high-throughput sequencing with Illumina's HiSeq 2500.

Thermo Fisher has the resources to pour even more funding into the Ion Torrent line. However, it is unknown what the new parent company's intentions are for Life Technologies, which has a huge portfolio of biotechnology products, any number of which will fit into Thermo Fisher's existing pipelines in sample prep, synthetic biology, forensics, and other research and clinical applications. Thermo Fisher is not known for its emphasis on R&D; in fact, in recent years, the smaller Life Technologies has occasionally outspent Thermo Fisher in this area.

Related Links:

Thermo Fisher Scientific
GE Healthcare
Life Technologies



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.